Suppr超能文献

成功使用依替巴肽治疗持续性左心室辅助装置血栓形成。

Successful treatment of a continuous flow left ventricular assist device thrombosis with eptifibatide.

机构信息

Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan, USA.

出版信息

ASAIO J. 2012 Nov-Dec;58(6):633-5. doi: 10.1097/MAT.0b013e318271bde2.

Abstract

Left ventricular assist device thrombosis is a rare but potentially lethal complication of mechanical circulatory support. Here, we present a case of successful treatment of a suspected HeartMate II thrombosis with the glycoprotein IIb/IIIa inhibitor, eptifibatide. The patient presented with signs and symptoms of heart failure, along with acute kidney injury and hemolytic anemia that did not respond to diuresis, inotrope support, or anticoagulation. Treatment with eptifibatide resulted in marked clinical and hemodynamic improvement within 24 hrs. The patient was transitioned to clopidogrel and discharged without further incident. Eptifibatide may represent a potential therapeutic option for patients with device thrombosis.

摘要

左心室辅助装置血栓形成是机械循环支持的一种罕见但潜在致命的并发症。在这里,我们报告了一例成功治疗疑诊 HeartMate II 血栓形成的病例,使用了糖蛋白 IIb/IIIa 抑制剂依替巴肽。该患者表现出心力衰竭的体征和症状,以及急性肾损伤和溶血性贫血,利尿剂、正性肌力药和抗凝治疗均无效。依替巴肽治疗在 24 小时内显著改善了临床和血液动力学状态。患者随后转为氯吡格雷治疗,并顺利出院,无进一步事件发生。依替巴肽可能是治疗装置血栓形成患者的一种潜在治疗选择。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验